[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aya-cancer-survivors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aya-cancer-survivors":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100638517","late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100638517",false,"NCT07622537","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Follow-AYA","Inclusion Criteria:\n\n* Female and male cancer patients aged between 15 and 39 years at diagnosis.\n* First diagnosed with any cancer disease between 01\u002F01\u002F2000 and 31\u002F12\u002F2025\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For testis\u002Fscrotal or gynaecological surgery.\n* Information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis\n* Cancer treated by surgery alone (except gynaecological\u002Ftesticular surgery)\n* Data from second malignant neoplasm diagnose and treatment\n* Adult subject of a measure of legal protection and\u002For patients with serious mental disorders","ALL","15 Years","39 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","In the past two decades, evidence-based knowledge on the prevalence and risk factors for fertility impairment, including infertility, following cancer and numerous cancer treatment regimens has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility potential, including success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex. Recent treatment regimens have continuously implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questions is highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of the quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale network structure of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian\u002Ftesticular dysfunction and\u002For fertility impairment and premature ovarian insufficiency\u002Foligo\u002Fazoospermia following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Ffertility treatment and patients' satisfaction related to these procedures in Europe shall be analysed to support patient-centric care.\n\nReproductive health counselling should not be restricted to evaluating the individual risk of gonadotoxicty and offering fertility preservation to those at risk. It also includes the sexual health, the use of post-cancer treatment contraception for those recommended to delay attempting pregnancy after a cancer diagnosis and the identification of potential obstetrical and neonatal risks to provide individualized, risk-adapted follow-up during pregnancy. An increased risk of obstetrical and neonatal complications has been reported for several conditions, including preterm delivery, pre-eclampsia, cardiac dysfunction, and gestational diabetes. Most available studies are based on population registry and lack of detailed information on critical factors such as the impact of the timing of pregnancy, method of conception or the type of cancer treatment received (e.g pelvic irradiation, anthracycline, targeted therapy, immunotherapy…), all of which may influence the outcomes.\n\nThe main objectives of this retrospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n• To establish harmonized databases with clinical data on pre- and post-cancer therapy and reproductive outcomes in AYA patients followed longitudinally.\n\n• To evaluate the impact of cancer treatment on long-term fertility according to cancer type and individual patients' characteristics (pre- and post-treatment) in male and female AYA populations.\n\n• To evaluate effect of cancer therapies on ovarian function in female AYA patients\n\n• To evaluate long-term effect on the endocrine function of the testis in male AYA patients i.e., the frequency of hypogonadism.\n\n• To evaluate the obstetrical and neonatal outcomes according to the disease and treatment.",[25,26,27,28,29,30],"Cancer","Infertility","Late Effects","Female Fertility","Male Fertility","AYA Cancer Survivors",[32,33,34],"cancer treatment induced late effects","infertility after cancer","AYA cancer survivours","NOT_YET_RECRUITING","2026-05-27",{"date":38,"type":39},"2026-06-03","ACTUAL",{"date":41,"type":21},"2026-06-01",{"date":43,"type":21},"2035-07-31",{"name":45,"class":46},"Karolinska Institutet","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100636885","helping-young-people-with-testicular-cancer-using-virtual-and-extended-reality-100636885","NCT07571499","Helping Young People With Testicular Cancer Using Virtual and Extended Reality","Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality","TRANSCEND-XR","Inclusion Criteria:\n\n1. Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles).\n2. Aged between 15 and 39 years at the time of study inclusion.\n3. Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and\u002For radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed.\n4. Permitted treatment modalities:\n\n   * Localised disease: orchiectomy with or without chemotherapy and\u002For radiotherapy.\n   * Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed.\n5. Willing and able to provide a valid and signed informed consent and\u002For assent, as appropriate.\n6. ECOG performance status 0-2.\n7. Patients accept to use personal smartphone\n8. Patients able to read and understand the local language\n\nExclusion Criteria:\n\n1. Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours).\n2. Non-germ cell TC.\n3. Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4.\n4. History of contralateral TC.\n5. Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator.\n6. Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy.\n7. Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment.\n8. AYA TC survivors with a \"currently active\" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 3 years.\n9. Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.","MALE",{"count":57,"type":21},245,"INTERVENTIONAL",[60],"NA","TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed.\n\nThe project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up.\n\nTRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help.\n\nThe ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.",[63,64,30,65],"Testicular Cancer","Testis Cancer","Survivor Patients",[67,68,69,70,71,72,73,74,75,76,77,78,79],"Testicular cancer survivors","Adolescents and young adults (AYA)","Survivorship care","Supportive care needs","Late effects of cancer treatment","Post-cancer follow-up","Quality of life","Patient education","Extended reality (XR)","Virtual reality in healthcare","Digital health intervention","Immersive digital tools","Long-term cancer effects","2026-04-30",{"date":82,"type":39},"2026-05-06",{"date":84,"type":21},"2027-01-04",{"date":86,"type":21},"2029-06-30",{"name":88,"class":46},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":111},"100561772","the-challenges-of-young-adults-with-cancer-100561772","NCT06594510","the Challenges of Young Adults With Cancer","AYANDRA Study: Addressing Youth and Adolescent Needs in Development, Research, and Advocacy","AYANDRA","Inclusion Criteria:\n\n* Age: 18 years old at survey participation, as long as aged 13-39 years old at diagnois;\n* Gastrointestinal cancer (colorectal, gastric, pancreatic) or breast cancer.\n\nExclusion Criteria:\n\n* Age: 18 years old at survey participation;\n* Patients 13 - 39 years old at diagnosis;\n* Hematologic malignancies or different cancers.","18 Years",{"count":99,"type":21},580,"The study aims to describe unmet needs of Adolescent \\& Young Adults (AYA) with gastrointestinal and breast cancers in relation to: a) quality of life, b) education, c) finances and Insurance, and d) childbearing and parenting in Europe",[102,30],"AYA Cancer Patients","2024-09-10",{"date":105,"type":39},"2024-09-19",{"date":107,"type":21},"2025-06-01",{"date":41,"type":21},{"name":110,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1]